This is a multi-center, randomized, blinded, two-period, two-sequence, crossover study, with
a minimum 3-week washout period between treatments.The study is designed to evaluate the
bioequivalence of SID530 to Taxotere.
It will be conducted in study participants with locally advanced or metastatic NSCLC who have
failed platinum therapy and also in participants with locally advanced or metastatic breast
cancer who have failed at least one line of chemotherapy.
Eligible study participants must be planning to have at least two consecutive 21-day cycles
with 75 mg/m2 docetaxel monotherapy.
The duration of study participation will be approximately 7 weeks. The study has three study
phases: Screening (<=1 week), Cycle 1 (21 days), and Cycle 2 (21 days).